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Abstract To determine whether unsaturated fatty acids induce 
changes in the mRNA level of plasminogen activator inhibitor 
type-1 (PAI-I), Northern analyses were performed on human 
umbilical vein endothelial cells (HUVEC) and vascular smooth 
muscle cells that were treated with two common fatty acids. 
Supplementation of cultured HUVEC with docosahexanoic a id 
(DHA) or with dihomogamma linolenic acid (DGLA), resulted 
in a concentration dependent, specific increase of the PAI-1 tran- 
script levels, which was detectable within 2 h. DHA and DGLA 
treatment of smooth muscle cells did not result in changes in the 
PAI-I mRNA levels. Homology search of the upstream regula- 
tory region of the PAI-1 gene sequences identified a consensus 
nucleotide sequence for a fatty acid-responsive element. Our re- 
suits indicate that unsaturated fatty acids selectively increase 
PAI-1 mRNA levels in endothelial cells, the primary source of 
circulating PAI-1 in vivo. 
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1. Introduction 
Plasminogen activators are serine proteases with restricted 
substrate specificity. Their primary substrate is plasminogen, 
which when cleaved forms plasmin, another serine protease 
which has a broader spectrum of activity. Plasmin mediates 
fibrinolysis, which is an important process for limiting the 
growth of fibrin clots within damaged blood vessels. The major 
circulating physiologic inhibitor of both tissue-type and uroki- 
nase-type plasminogen activators in vivo is plasminogen activa- 
tor inhibitor type 1 (PAI-1), a member of the serpin class of 
protease inhibitors (for review see [1]). Serum PAl-1 levels have 
been found to be elevated in young [2] and old [3] survivors of 
myocardial infarction and in patients with other thrombotic 
disorders uch as deep vein thrombosis [4]. In addition, there 
is a reasonably strong positive correlation between triglyceride 
levels and PAI-1 levels in plasma [2,5]. Furthermore, triglyc- 
eride-rich lipoproteins uch as very low density lipoprotein 
have been shown to increase PAI-1 secretion from cultured 
endothelial cells [6]. 
It has been suggested that dietary fish oil, consisting mainly 
of unsaturated o9-3 fatty acids, provides protection from coro- 
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nary artery disease and may reduce elevated triglyceride l vels 
[7--9]. Consumption of fish oil, or plant seed oils rich in unsat- 
urated o9-6 fatty acids has been shown to improve symptoms 
in patients with chronic inflammatory diseases, including rheu- 
matoid arthritis [10,11], Paradoxically, in human trials, fish oil 
has been demonstrated to significantly increase the level of 
plasminogen activator inhibitor type-1 (PAI-1) in plasma of 
patients and healthy humans [12-15]. However, a model that 
would explain the beneficial clinical effects, or the molecular 
mechanism by which the fatty acids exert their stimulatory 
action on PAI-1 level, has not been elucidated. 
Endothelial cells readily take up fatty acids which are added 
to the culture medium [16]. The fatty acid either incorporates 
into cellular lipids or enters the fatty acid metabolic pathway 
[16,17]. Exogenously provided fatty acid can serve as a biolog- 
ical effector [18]. Fatty acids can also be directly involved in 
regulating ene expression by binding to specific, fatty acid- 
responsive transcription factors [19-25]. 
As part of our investigation of the plasminogen activator 
system of endothelial and vascular smooth muscle cells, we 
undertook the present study to evaluate the role of unsaturated 
fatty acids in the regulation of PAI-1 mRNA. Our results indi- 
cate that dihomogamma linolenic acid (DGLA) and 
docosahexanoic a id (DHA), increase the steady state PAI-1 
mRNA level in cultured human endothelial cells. The stimula- 
tory effect is mRNA and cell specific. A potential fatty acid 
responsive lement in the regulatory region of the PAI-1 gene 
is also identified. 
2. Materials and methods 
2.1. Fatty acids 
Docosahexanoic a id (DHA; C22:6, co-3) and dihomogamma lino- 
lenic acid (DGLA; C20: 3, co-6), (all from Cayman Chemical, Ann 
Arbor, MI) were stored in ethanol at 0.4 M concentration, at-20 ° C. 
2.2. Cell culture 
Human umbilical vein endothelial cell (HUVEC) were propagated 
from pooled primary cultures of umbilical veins as previously described 
[26]. Briefly, endothelial cells were grown on fibronectin coated flasks 
(Nunclon) to confluence and passaged 2-3 times in complete medium 
containing Medium 199 (Gibco, Gaithersburg, MD) supplemented 
with 10% heat-inactivated fetal calf serum (FCS; Flow Laboratories, 
McLean, VA), penicillin (100 U/ml) and streptomycin (100 ktg/ml) 
(Gibco), and endothelial cell growth factor (ECGF, partially purified 
acidic FGF; ~ 150 ng/ml) and heparin (90 gg/ml). Cells were split 1 : 2 
and fed every 2-3 days. Human vascular smooth muscle cells (SMC) 
were cultured from umbilical vein using the explant echnique [27]. 
Briefly, the SMC were cultured in DMEM (Gibco) and Ham's F-12 
(Gibco) (1:1 ratio) containing medium that was supplemented with 
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FCS, penicillin and streptomycin as described above. For any given 
experiment, cells at second or third passage level were seeded into 
fibronectin-coated Petri dishes (10 cm in diameter). On the following 
day, the medium was replaced with fresh medium, and the cells were 
further cultured. On the next day when the cells reached confluency, 
the culture medium was supplemented with fatty acid and the cells were 
further cultured for the indicated time period. Control experiments 
testing the effect of solvent ethanol, up to a 1.8% final concentration, 
were also included. In the time course experiments fresh medium was 
added to the cells at the time of fatty acids supplementation. At the end 
of the fatty acid treatments cells appeared normal under phase contrast 
microscopy. Viability was >98% using Trypan blue exclusion test as 
criterion. 
2.3. RNA isolation 
Total cytoplasmic RNA was isolated by immediate solubilization of 
the cells in a one-phase solution of phenol and guanidine thiocyanate 
(RNazol, Biotecx, Houston, TX) according to the manufacturers rec- 
ommendation. Briefly, culture medium was removed from the cells and 
1 ml RNazol was added to each dish to lyse the cells. A scraper was 
used to collect he lysate. The lysate was extracted with chloroform, and 
the RNA in the aqueous phase was precipitated with isopropanol. The 
RNA was quantified by absorbance at260 nm. The average yield was 
~ 70-90~g RNA per dish. The quality of the RNAs was tested on agarose 
gel by analyzing the integrity of the UV visualized, ethidium bromide 
stained 28S and 18S rRNAs. 
2.4. Northern blot analysis 
RNA (l 0 pg) was denatured and separated on 1% agarose/formalde- 
hyde gel, then transferred toNytran membrane (Schleicher and Schuell, 
Keene, NH) according to standard procedures [28]. The RNA was fixed 
to the membrane with ultraviolet irradiation and baked in a vacuum 
oven at 70°C for 30 rain to eliminate traces of formaldehyde. The 
membrane was prehybridized in 5 × SSC, 50% (v/v) deionized forma- 
mide (Clonetech, Palo Alto, CA), 5 x Denhardt's olution (1 × Den- 
hardt's olution contains 0.02% BSA, 0.02% Ficoll 400, 0.02% Polyvi- 
nyl pyrrolidone), 0.1% SDS, 10 mM Tris-HC1 (pH 7.5) and 0.1 mg/ml 
sonicated Salmon sperm DNA (Sigma, St. Louis, MO) at 42°C for 2 h 
in a hybridization oven (Techne, Princeton N J). The hybridization was 
performed at 42°C for 16-22 h in the prehybridization solution which 
was supplemented with the appropriate radiolabeled and denatured 
probe. To probe the Northern blots, 25 ng of DNA was labeled using 
[~-32P]dCTP (Amersham, Arlington Heights, IL) and a random prime 
labeling kit (Boehringer Mannheim, Indianapolis, IN). The blots were 
washed three times with 2 x SSC and 0.1% SDS at room temperature 
for 15 min, then washed once with 0.1 × SSC and 0.1% SDS at 52°C 
for 10 min. The filters were exposed to Kodak XAR film using an 
intensifier screen at -70°C for 4-48 h. To obtain exposures in the linear 
range of the film, the same Northern blots were exposed for different 
time periods. Before reprobing, the filters were stripped of the previous 
probe by shaking at 90°C in 0.01% SDS solution for 20 rain. They were 
then re-exposed with films to confirm successful stripping. Autoradi- 
ograms of the Northern blots were quantified by densitometry using a 
Microtech scanner and image analysis program (Image V1.4 NIH). 
Densitometric values were first adjusted for differences of the back- 
ground, then normalized to values of the same blot reprobed with 
GAPD. Some of the Northern blots were also quantitated using storage 
phosphor technology (PhosphorImager, Molecular Dynamics, Sun- 
nyvale, CA). 
2.5. Probes 
The following specific cDNAs were used to probe the blot. For 
uPAR transcripts the probe was a ~ 1.1 kb insert from pGEMuPAR 
which contains the full coding sequence for human uPAR [29]. For the 
detection of PAI-1 mRNA, a purified 1.9 kb human specific cDNA 
from pUC19-PAI-1 (kindly provided by Dr. T.C. Wun of Monsanto 
Co.) was used. The glyceraldehyde-3-phosphate dehydrogenase 
(GAPD) transcripts were detected by using the linearized plasmid 
pHcGAP (ATCC, Rockville, MD). For ~-enolase mRNA detection an 
RT-PCR amplified ~ 1.1 kb product was used as probe [30]. The human 
fl-actin specific probe was a 620 bp long cDNA that was obtained in 
RT-PCR amplification using specific primers and HUVEC mRNA. 
The primers were designed based on thefl-actin sequence obtained from 
GenBank (Accession Number: X00351). The 5'-primer (5'-CAAGGC- 
CAACCGCGAGAAG-3') corresponds to nucleotides 372395, the 
3"-primer (5'-CAGTGATCTCCTTCTGCATC-3') corresponds to nu- 
cleotides 996-977. Probes obtained by PCR amplification were gel 
purified before labeling. 
2.6. Nucleotide sequence analyses 
Sequence information was retrieved from GenBank R81.0 by the 
MacDNASIS V3.2 program (Hitachi, San Bruno, CA) using the fol- 
lowing Accession Numbers: human PAI-1 gene, X06692; mouse PAI-1 
gene, M33961; rat S14 gene, M33553; mouse fatty acid binding protein 
(aP2) gene, M84651; [31]. Sequence alignment was performed with the 
MegAlign program (DNASTAR, Madison, WI). 
3. Results 
3.1. DGLA and DHA increase the level o f  PAI-1 mRNA o f  
cultured endothelial cells 
It has been shown that culturing HUVEC in medium supple- 
mented with 150/ IM of a variety of saturated or unsaturated 
fatty acids results in dramatic hanges in the fatty acid compo- 
sition of the cells without any detectable ffect on cell counts 
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Fig. 1. The effect of DGLA and DHA on mRNA level of human 
endothelial cells. (A) Human umbilical vein endothelial cells were 
treated with DGLA and DHA for 22 h. Total RNAs were isolated and 
l0 pg aliquots were analyzed on Northern blot using the following 
probes: PAI-1 (plasminogen activator inhibitor-1), GAPD (glyceralde- 
hyde phosphate dehydrogenase), uPAR (urokinase receptor), fl-actin 
and ~-enolase. (B) Densitometric analyses of the autoradiograms. The 
arbitrary values were standardized for GAPD mRNA to correct for 
uneven sample loading. Data are presented relative to the specific 
mRNA of the control untreated cells. 
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Fig. 2. PAI-1 mRNA induction by DGLA and DHA. Human endothe- 
lial cells were treated with 150 ¢tM DGLA or DHA for 2 h. Total RNAs 
were isolated and 10 pg aliquots were analyzed on Northern blot using 
PAI-1 and GAPD as probes. 
or their viability [32]. To evaluate if the supplementary fatty 
acids can specifically regulate the level of mRNA in endothelial 
cells, we selected treatment conditions similar to those used for 
the metabolic studies [32,33]. 
Confluent hird passage HUVEC were cultured in media 
with or without DGLA or DHA supplementation. Cells were 
harvested 22 h later and total RNA prepared. Autoradiograms 
of the Northern blots and their densitometric analyses are 
shown in Fig. 1 A and B, respectively. Cultured HUVEC ex- 
pressed detectable l vels of both the 3.4 and 2.4 kb PAI-1- 
specific mRNA species. Addition of DGLA or DHA to the 
culture media resulted in concentration dependent increases in 
the levels of both PAI-1 transcripts. The effect appeared to be 
specific because steady state levels of mRNA for uPAR, an- 
other component of the endothelial cell plasminogen activator 
system was not substantially changed, nor were transcript levels 
for fl-actin, GAPD or ~-enolase. In control experiments, corre- 
sponding amounts of solvent ethanol, up to a 1.8% final con- 
centration, had no detectable effect on cell morphology or on 
mRNA levels of PAI-1 and GAPD. Higher concentrations of 
fatty acids (~600 ¢tM) were toxic to HUVEC and resulted in 
decreases in steady state PAl-1 mRNA level (not shown). Stim- 
ulation with oleic acid (75/zM) performed in parallel with the 
experiment presented in Fig. 1, resulted in a 3.4-fold increase 
in PAI-1 mRNA (not shown). Four independent experiments 
revealed that the mean fold increase in PAI-1 mRNA levels 
compared to the untreated control was 2.2 + 0.5 (+S.E.M., 
P < 0.05) for DGLA (150 pM). In 8 independent experiment, 
there was a 2.3 + 0.6-fold increase (P < 0.0003) for DHA (150 
pM). In time course studies, at the earliest point investigated 
(2 h), a 1.7-fold increase in PAI-1 mRNA level was detected for 
both DGLA and DHA (150/tM), as shown in Fig. 2. 
Some variability in the magnitude of the stimulatory effect 
was noted, depending on the baseline absolute level of PAI-1 
mRNA. In three additional experiments where baseline PAI-1 
mRNA levels were found to be substantially higher (~ 5-fold) 
than in the other 12 experiments, nosignificant further increase 
in PAI-1 transcript levels could be detected, suggesting that the 
stimulation of PAI-1 mRNA by fatty acids required no more 
than moderately high PAI-1 steady state mRNA levels at 
baseline to observe the effect. 
3.2. DGLA and DHA effect on the level of  PAI-1 mRNA of 
cultured vascular smooth muscle cells 
To determine if the fatty acid stimulatory effect was present 
in other vascular cells known to secrete PAI-1 in culture, we 
tested the effect of DGLA and DHA on steady state PAI-1 
mRNA levels in cultured human umbilical vein smooth muscle 
cells in a similar fashion as described above for HUVEC. Auto- 
radiograms of the Northern blots and their densitometric anal- 
yses are shown in Fig. 3 A and B, respectively. Four inde- 
pendent experiment revealed that DGLA and DHA treatment 
of SMC did not result in a significant change in PAI-1 tran- 
script levels. The mRNA levels for uPAR, GAPD and c~-eno- 
lase were also unchanged. The absolute PAI-1 levels in these 
experiments were similar to levels in HUVEC studied in parallel 
that had demonstrated significant enhancement wi h fatty acid. 
This suggest that lack of effect in SMC was not due to very high 
baseline PAl-1 mRNA levels. Finally, as shown in Fig. 4 (which 
depicts the individual data for experiments performed with 
DGLA and DHA at 150 ¢tM in both cell types), the stimulatory 
effect is mainly and consistently seen only in endothelial cells, 
although the degree of the effect is somewhat variable. 
4. Discussion 
Results of these experiments demonstrate hat DGLA and 
DHA enhance steady state levels of PAl- 1 mRNA in cultured 
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Fig. 3. The effect of DGLA and DHA on mRNA level of human 
vascular smooth muscle cells. (A) Human vascular smooth muscle cells 
were treated with DGLA and DHA for 24 h. Total RNAs were isolated 
and 10/zg aliquots were analyzed on Northern blot using the probes 
described in the legend of Fig. 1. (B) Densitometrical analyses of the 
autoradiograms. The arbitrary values were standardized for GAPD 
mRNA to correct for uneven sample loading. Data are presented rela- 
tive to the specific mRNA of the control untreated cells. 
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human endothelial cells. DGLA and DHA treatment increases 
PAI- 1 mRNA levels of HUVEC in a concentration dependent 
fashion, but does not alter steady state levels of fl-actin, 
ct-enolase and GAPD transcripts. Tissue specificity of these 
effects are suggested by the observation that DGLA and DHA 
treatment of cultured vascular smooth muscle cells have no 
effects on levels of PAl- l ,  uPAR, ct-enolase and GAPD 
mRNAs. These results support the basic finding obtained in 
clinical trials based on dietary studies [12-15], that polyunsatu- 
rated fatty acids increase circulating PAI-1 levels. 
Our results indicate that DGLA and DHA selectively in- 
crease the steady state level of PAl-1 mRNA. The mechanism 
by which these unsaturated fatty acids exert this stimulatory 
effect is not known. One potential explanation could be that the 
fatty acids are directly involved in transcriptional regulation of 
the PAI-1 gene. An interesting feature of the polyunsaturated 
fatty acids is their ability to regulate the expression of genes by 
binding to fatty acid responsive factors [22,23,25]. Sloots et al. 
identified consensus nucleotide sequences in the upstream re- 
gion of five oleic acid-inducible genes of the diploid yeast Can- 
dida lropicalis. By using mutational analyses they confirmed 
these sequences to be fatty acid-responsive r gulatory elements 
[19]. Searching for sequence homology in the Y-flanking region 
of the human PAl- 1 gene, we could identify sequences that are 
highly homologous to the consensus fatty acid-responsive ele- 
ment (Fig. 5). We could also localize these consensus sequences 
in the promoter egion of the murine PAI-1 gene, as well as in 
the regulatory regions of the rat S14 and murine aP2 genes, 
both of which have been reported to be transcriptionally regu- 
lated by fatty acids [23,25] (Fig. 5). These findings suggest a 
potential mechanism for the direct involvement of the unsatu- 
rated fatty acids in the stimulation of PAI-1 transcription. 
In conclusion, the present study demonstrates that unsatu- 
rated fatty acids can induce PAI-1 mRNA in endothelial cells, 
which are the primary source for PAl-1 production in vivo [34]. 
Based on the identification of a fatty acid-responsive r gulatory 
element in the PAl-1 gene we can hypothesize that DHA and 
DGLA might induce PAl-1 transcription directly. These find- 
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Fig. 5. Homology alignment of established and potential fatty acid- 
responsive gene regulatory elements. Conserved fatty acid-responsive 
sequences of oleic acid inducible genes of yeast (HDE, peroxisomal 
trifunctional enzyme hydratase-dehydrogenase-epimerase; POX4,fatty 
acyl-CoA oxidase; CATL, catalase; POX18, peroxisomal 18-kDa pro- 
tein; P450ALK, alkane-inducible cytochrome P450) [19] are aligned 
with highly homologous regulatory sequences of human and murine 
PAl-1, rat S 14 and murine aP2 genes. Numbering indicates the nucleo- 
tide distance upstream from the transcription start site (+ 1). Residues 
that differ from the consensus are circled, aConsensus fatty acid-respon- 
sive regulatory sequence proposed by Sloots et al. [19] based on the 
analyses of the shown five yeast genes. 
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ings suggest a mechanism whereby circulating PAI-1 are in- 
creased in humans consuming unsaturated fatty acids. 
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